Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients-Reference-Cited by-同舟云学术

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients

Published:2021-10 Issue:4 Volume:11 Page:1-5
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Aldweib Nael¹²^ORCID,Verlinden Nathan J.¹,Kassis‐George Hayah¹,Raina Amresh¹

Affiliation:

1. Section of Advanced Heart Failure and Pulmonary HypertensionCardiovascular InstituteAllegheny General HospitalAllegheny Health NetworkAllegheny General HospitalPittsburghUSA

2. Adult Congenital Heart Disease ProgramKnight Cardiovascular InstituteOregon Health Science UniversityPortlandUSA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/20458940211036623

Reference9 articles.

1. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS‐based risk assessment strategies;Benza RL;Chest,2019

2. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report;Klinger JR;Chest,2019

3. Selexipag for the treatment of pulmonary arterial hypertension;Sitbon O;N Engl J Med,2015

4. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution;Yanaka K;Eur Respir J,2020

5. EXPRESS: transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients;Holthaus N;Pulm Circ

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the management of pulmonary arterial hypertension patients in Spain;REC: CardioClinics;2023-10

2. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report;ESC Heart Failure;2023-06-19

3. Side effects of agents that influence corticotrophins, corticosteroids, and prostaglandins;Side Effects of Drugs Annual;2023

4. Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension;Pulmonary Circulation;2022-10

5. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients;Frontiers in Cardiovascular Medicine;2022-09-20